Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain ...

The antigen-binding site of the antibody has a unique structure that allows it to bind antigen in a highly specific manner. Functional and structural studies of two potent antibodies isolated from ...

The first-in-class and so far best-in-class PD-1xVEGF bispecific antibody ivonescimab has set the bar for competitors in the pipeline for a superior clinical profile compared with anti-PD-1 ...